Drugs / 3, 4, 3-LI(1, 2-HOPO)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05628961 | Mar 2023 → Aug 2025 | — | SRI International | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3, 4, 3-LI(1, 2-HOPO) | “HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.” NCT05628961 ↗ |
| Route | Oral | “Participants receive an oral single dose of HOPO 14-1 in the fasted condition on Day 1.” NCT05628961 ↗ |